• Product nameAnti-CACNB4 antibody
    See all CACNB4 primary antibodies
  • Description
    Goat polyclonal to CACNB4
  • SpecificityThis antibody is expected to recognise all three reported isoforms.
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Cow, Pig, Chinese hamster
  • Immunogen

    Synthetic peptide:


    , corresponding to near C terminal amino acids 491-503 of Human CACNB4

  • Positive control
    • Human Bone Marrow lysate


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 0.5% BSA, Tris buffered saline, pH 7.3
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab58601 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesPeptide ELISA: antibody detection limit dilution 1:4,000.
    WB: Use at a concentration of 0.2 - 0.6 µg/ml. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionThe beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
    • Tissue specificityExpressed predominantly in the cerebellum and kidney.
    • Involvement in diseaseGenetic variations in CACNB4 are the cause of susceptibility to idiopathic generalized epilepsy type 9 (IGE9) [MIM:607682]. IGE9 is characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.
      Genetic variations in CACNB4 are the cause of susceptibility to juvenile myoclonic epilepsy type 6 (EJM6) [MIM:607682]. EJM6 is a subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.
    • Sequence similaritiesBelongs to the calcium channel beta subunit family.
      Contains 1 SH3 domain.
    • Information by UniProt
    • Database links
    • Alternative names
      • CAB4 antibody
      • CACB4_HUMAN antibody
      • Cacnb4 antibody
      • CACNLB4 antibody
      • Calcium channel voltage dependent beta 4 subunit antibody
      • Calcium channel voltage dependent subunit beta 4 antibody
      • Calcium channel voltage-dependent subunit beta 4 antibody
      • Dihydropyridine sensitive L type calcium channel beta 4 subunit antibody
      • EA5 antibody
      • EIG9 antibody
      • EJM antibody
      • EJM4 antibody
      • EJM6 antibody
      • Voltage-dependent L-type calcium channel subunit beta-4 antibody
      see all

    Anti-CACNB4 antibody images

    • Anti-CACNB4 antibody (ab58601) at 0.2 µg/ml + Human Bone Marrow lysate at 35 µg

      Predicted band size : 58 kDa
      Observed band size : 58 kDa

    References for Anti-CACNB4 antibody (ab58601)

    ab58601 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab58601.
    Please use the links above to contact us or submit feedback about this product.